



## Abacavir and Lamivudine Tablets

<b>Type of Posting</b>	Revision Bulletin
<b>Posting Date</b>	30-Jan-2026
<b>Official Date</b>	1-Feb-2026
<b>Expert Committee</b>	Small Molecules 1

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 1 Expert Committee has revised the Abacavir and Lamivudine Tablets monograph. The purpose of this revision is to add *Dissolution Test 2* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). The revision also necessitates a change in the table numbering in the test for *Organic Impurities*. *Labeling* information has been incorporated to support the inclusion of *Dissolution Test 2*.

- *Dissolution Test 2* was validated using the Symmetry C18 brand of column with L1 packing. The typical retention times for lamivudine and abacavir are about 2.7 and 3.5 min, respectively.

The Abacavir and Lamivudine Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Brice Wagner, Scientist IV (301-998-6832 or [brice.wagner@usp.org](mailto:brice.wagner@usp.org)).